Form 4 for TVTX Travere Therapeutics, Inc.
Accepted 2026-02-24 00:00:00 ET · period of report 2026-02-20 · accession 0001763494-26-000003 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-02-24 | 2026-02-20 | TVTX | Dube Eric M | CEO, Dir | M - OptEx | $15.46 | +60.0K | 492.9K | +14% | +$927.6K |
| D | 2026-02-24 | 2026-02-20 | TVTX | Dube Eric M | CEO, Dir | S - Sale+OE | $30.10 | -60.0K | 432.9K | -12% | -$1.81M |
| D | 2026-02-24 | 2026-02-20 | TVTX | Dube Eric M | CEO, Dir | M - OptEx | $0.00 | -60.0K | 60.0K | -50% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-02-20 | M | A | 60,000 | $15.46 | 492,886 | D | — | — | |
| 2 | Common | Common Stock | 2026-02-20 | S | D | 60,000 | $30.10 | 432,886 | D | — | — | (F2) The weighted average sale price for the transaction reported was $30.0961, and the range of prices were between $30.00 and $30.325. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. |
| 3 | Derivative | Employee stock option (right to buy) | 2026-02-20 | M | D | 60,000 | $0.00 | 60,000 | D | $15.46 · — to 2030-01-31 | 60,000 Common Stock | (F3) The stock option is fully vested and exercisable. |